Italfarmaco entrusts Maxer with the CTD and DT activities

We are pleased to announce that last March Italfarmaco S.p.A.  appointed Maxer Consulting to carry out its Clinical Trial Disclosure (CTD) and Data Transparency activities for 2023.

The agreement provides for Maxer to ensure Italfarmaco’s compliance with the results of the clinical studies entrusted to Maxer by publishing them on the platforms according to the regulations in force in the European Union and the United States. The results will be posted on the EudraCT and PRS platforms, respectively. Concerning the latter, the publication of the Protocol and Statistical Analysis Plan, anonymised and redacted, is also envisaged.